A Single-blind Phase 1 Study Assessing the Safety, Immunogenicity and Low Density Lipoprotein Cholesterol (LDLc)-Lowering Activity of 2 Different Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Targeting AFFITOPE Vaccines in Healthy Subjects
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 22 Sep 2016
At a glance
- Drugs ATH 04 (Primary) ; ATH 06 (Primary) ; Adjuvants
- Indications Atherosclerosis
- Focus Adverse reactions
- Acronyms AFF012
- Sponsors AFFiRiS
- 09 Sep 2016 Planned primary completion date changed from 1 Apr 2016 to 1 Sep 2017.
- 27 May 2016 Planned End Date changed from 1 Nov 2016 to 1 Dec 2016.
- 03 Feb 2016 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.